Efficacy of 1-Year Cavacurmin® Therapy in Reducing Prostate Growth in Men Suffering from Lower Urinary Tract Symptoms

Abstract

We aim to assess the effect of Cavacurmin® on prostate volume (PV), lower urinary tract symptoms (LUTS) and micturition parameters in men after 1 year of therapy. From September 2020 to October 2021, data from 20 men with LUTS/benign prostatic hyperplasia and PV ≥40 mL who were on therapy with α1-adrenoceptor antagonists plus Cavacurmin® were retrospectively compared with 20 men on only α1-adrenoceptor antagonists. Patients were evaluated at baseline and after 1 year using the International Prostate Symptom Score (IPSS), prostate-specific antigen (PSA), maximum urinary flow (Qmax) and PV. A Mann–Whitney U-test and Chi-square were used to assess the difference between the two groups. A comparison of paired data was performed with the Wilcoxon signed-rank test. Statistical significance was set at p-value < 0.05. There was no statistically significant difference in baseline characteristics between the two groups. At the 1-year follow-up, PV [55.0 (15.0) vs. 62.5 (18.0) mL, p = 0.04)], PSA [2.5 (1.5) ng/mL vs. 3.05 (2.7) vs. p = 0.009] and IPSS [13.5 (3.75) vs. 18 (9.25) p = 0.009] were significantly lower in the Cavacurmin® group. Qmax was significantly higher in the Cavacurmin® group [15.85 (2.9) vs. 14.5 (4.2), p = 0.022]. PV was reduced to 2 (5.75) mL in the Cavacurmin® group from baseline, while it increased to 12 (6.75) mL in the α1-adrenoceptor antagonists group (p < 0.001). PSA decreased in the Cavacurmin® group [−0.45 (0.55) ng/mL], whereas it increased in the α1-adrenoceptor antagonists group [0.5 (0.30) ng/mL, p < 0.001]. In conclusion, one-year Cavacurmin® therapy was able to block prostate growth with a concomitant decrease in PSA value from baseline. The association of Cavacurmin® with α1-adrenoceptor antagonists had a more beneficial effect compared to patients on α1-adrenoceptor antagonists alone but this needs further larger studies to be confirmed, particularly in the long-term.

Phytotherapy Might Have a Role in Reducing Unnecessary Prostate Biopsies: Results from an Exploratory, Randomized Controlled Trial of Two Different Phytotherapeutic Agents

“…The difference between Prostaflog ® and Serenoa Repens in our study is probably due to the presence of compounds, such as curcuma, boswellia, urtica dioica and pinus pinaster. In particular, boswellia, urtica dioica and soybean extracts have been shown to have a measurable effect on the prostate [10]. In particular, Cai et al recently demonstrated that Prostaflog ® is able to decrease prostate inflammation by affecting the IL-8 level [20].…”

“…Several phytotherapeutic and nutraceutical compounds show anti-inflammatory characteristics and are of interest in this field [9]. In the last years, the use of phytotherapeutic compounds such as curcuma longa, boswellia, urtica dioica, pinus pinaster has been explored in the management of urological diseases and has demonstrated minimal side-effects [10,11]. Based on the evidence above, we wanted to evaluate if a combination of Curcuma Longa, Boswellia, Pinus pinaster and Urtica dioica (Prostaflog ® ) might have a role in decision making before prostate biopsy.…”

Phytotherapy Might Have a Role in Reducing Unnecessary Prostate Biopsies: Results From an Exploratory Randomized Controlled Trial of Two Different Phytotherapeutic Agents

“…The difference between Prostaflog ® and Serenoa Repens in our study is probably due to the presence of compounds, such as curcuma, boswellia, urtica dioica and pinus pinaster. In particular, boswellia, urtica dioica and soybean extracts have been shown to have a positive effect on the prostate health [11]. In particular, Cai et al recently demonstrated that Prostaflog ® is able to decrease prostate inflammation by affecting the IL-8 level [28].…”

“…Several phytotherapeutic and nutraceuticals compounds show anti-inflammatory characteristics and are of interest in this field [10]. In the last years, the use of phytotherapeutic compounds such as curcuma longa, boswellia, urtica dioica, pinus pinaster has been explored in the management of urological disease and have demonstrated minimal side-effects [11][12][13][14]. Based on the evidence above, we wanted to evaluated if a combination of Curcuma Longa, Boswellia, Pinus pinaster and Urtica dioica (Prostaflog ® ) might have a role in decision making before prostate biopsy.…”